F

or the past three years, various governments and patient advocacy groups have clamored for lower-cost hepatitis C medicines, given the high cure rate for these pricey new drugs. Now, a new study finds that upfront treatment with cheaper generic versions can offer a substantial payback.

Using a mathematical model for patients in India, researchers found that copycat versions costing around $300 would increase life expectancy by more than eight years and reduce lifetime health care costs by more than $1,300 per person. Moreover, treatment became cost effective in two years and upfront costs could be recovered inside of 10 years, according to the analysis published in PLOS ONE.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Facts that are … puzzling? “researchers found that copycat versions costing around $300…” And where will this $300 course of treatment come from vs. current $1,000/pill? Or does this imply $300/pill without saying it?

    • Hi Observer
      Thanks for the note. The researchers used a model and based it on the price for which generic versions of some drugs are available at that price.
      There is a link to the study, so you can read more.
      ed at pharmalot

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.